Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Receivables (2020 - 2023)

Historic Receivables for Revolution Medicines (RVMDW) over the last 4 years, with Q4 2023 value amounting to $1.3 million.

  • Revolution Medicines' Receivables fell 7316.5% to $1.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.3 million, marking a year-over-year decrease of 7316.5%. This contributed to the annual value of $1.3 million for FY2023, which is 7316.5% down from last year.
  • Latest data reveals that Revolution Medicines reported Receivables of $1.3 million as of Q4 2023, which was down 7316.5% from $309000.0 recorded in Q3 2023.
  • In the past 5 years, Revolution Medicines' Receivables ranged from a high of $12.8 million in Q4 2020 and a low of $309000.0 during Q3 2023
  • Moreover, its 4-year median value for Receivables was $5.4 million (2022), whereas its average is $5.3 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 1383.48% in 2022, then tumbled by 9374.49% in 2023.
  • Quarter analysis of 4 years shows Revolution Medicines' Receivables stood at $12.8 million in 2020, then tumbled by 53.63% to $5.9 million in 2021, then dropped by 21.18% to $4.7 million in 2022, then crashed by 73.16% to $1.3 million in 2023.
  • Its Receivables stands at $1.3 million for Q4 2023, versus $309000.0 for Q3 2023 and $2.5 million for Q2 2023.